Compared with TNF inhibitors, IL-23 inhibitors were associated with a lower risk of paradoxical eczema (hazard ratio [HR], 0.39; 95% CI, 0.19-0.81) (Table 3). This evidence concerns the gene TNF and Eczematoid dermatitis.